APPLICATION
ANDA219167
TYPE
ANDA
ORIGINAL APPROVAL
2026-01-06
LATEST ACTION
2026-01-06
ROUTE
INTRAVENOUS, SUBCUTANEOUS, INTRAVENOUS, SUBCUTANEOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription
Products
BORTEZOMIBPrescription
BORTEZOMIB 1MG/VIAL · POWDER · INTRAVENOUS, SUBCUTANEOUS
BORTEZOMIBPrescription
BORTEZOMIB 2.5MG/VIAL · POWDER · INTRAVENOUS, SUBCUTANEOUS
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.